The TIMER2 database analysis revealed that GNL3L was immensely expressed in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), CHOL (cholangiocarcinoma), COAD (colon adenocarcinoma), ESCA, GBM (glioma multiforme), HNSC (head and neck squamous cell carcinoma), LIHC (hepatocellular G liver cancer), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), READ (rectal adenocarcinoma), STAD (gastric cancer), and UCEC (endometrial carcinoma). Here, GNL3L is linked to invasive breast carcinoma.